Lilly's once daily leukemia pill Jaypirca, layered onto a planned venetoclax rituximab course, cut the risk of relapse or death by 45% in a 639 patient Phase 3 trial that the company calls the first to beat a venetoclax based control in relapsed CLL.
For patients whose chronic lymphocytic leukemia (CLL) or its sibling small lymphocytic lymphoma (SLL) returned after a first round of therapy, a three-drug plan with a built-in stop date cut the risk of relapse or death by 45% in a 639-patient Phase 3 trial reported by Eli Lilly on June 14, 2026. The experimental arm added Jaypirca (pirtobrutinib), a once-daily pill that blocks a signaling protein leukemia cells rely on, to a two-year course of venetoclax and rituximab, drugs that together form a common second-line backbone for this disease.
The 45% number is progression-free survival, not overall survival, and it is the first Phase 3 result in CLL to beat a venetoclax-containing control arm. The trial, called BRUIN CLL-322, randomized patients whose disease had come back or stopped responding to earlier treatment. The independent review committee assessed progression-free survival at a hazard ratio of 0.55 (95% CI 0.40 to 0.75, p=0.0001), which Lilly translates to a 45% reduction in the risk of disease progression or death when pirtobrutinib was layered onto venetoclax and rituximab.
Roughly four in five patients in the trial had already been on a covalent BTK inhibitor, a class of pills that bind the same growth-signal target irreversibly and that dominate the modern first-line setting. When those older pills stop working, often because the leukemia develops resistance mutations, the non-covalent BTK inhibitor class is designed to step in. Pirtobrutinib binds the same BTK protein reversibly, which is the mechanistic reason it can still work after covalent failure. The 79.8% prior covalent-BTK figure comes from the Lilly release, and it is the population this combination is actually built for.
The second-line question the trial does not answer is whether sequencing a covalent BTK inhibitor first and then a non-covalent BTK inhibitor after produces better outcomes than going straight to a BTK-plus-venetoclax strategy. The control arm here was venetoclax and rituximab alone, not a covalent BTK inhibitor layered with venetoclax, which is the combination some oncologists favor for fit, relapsed patients. Overall survival data from BRUIN CLL-322 are not yet mature, and the triplet adds toxicity on top of an already myelosuppressive backbone, particularly cytopenias and infection risk that need real-world confirmation rather than just a press-release sketch.
The "time-limited" framing is also specific. It refers to a two-year course of venetoclax plus rituximab, with pirtobrutinib layered on for the experimental arm. That is a real finish line for patients who would otherwise face indefinite BTK inhibition, and the planned treatment-free interval after the two years is the patient-facing payoff the wire story skips. Lilly called the result the first Phase 3 to demonstrate superiority over a venetoclax-containing control in CLL, a characterization the company is entitled to make, though independent confirmation will come when the data are presented at the 2026 European Hematology Association (EHA) Annual Meeting in a late-breaking oral session, Lilly said.
The watch item for clinicians and investors is what the safety and overall survival readouts from the EHA presentation add, and whether regulators treat the BRUIN CLL-322 hazard ratio as enough to support a label expansion for Jaypirca into the second-line, post-covalent-BTK setting. Full data, adverse-event detail, and any subgroup analyses are still pending; the June 14, 2026 release is a topline read, and the EHA late-breaking oral is where the rest of the picture will emerge.